$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

$slrx Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000161521918000061 Filed on November 05, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$163.1K	$469.1K	$282.8K
YoY Change	-42.34%	13.41%	-5.38%
Cost Of Revenue	$74.93K	$91.94K	$133.3K
YoY Change	-43.8%	-38.2%	-0.27%
Gross Profit	$88.13K	$377.1K	$149.5K
YoY Change	-41.04%	42.39%	-9.51%
Gross Profit Margin	54.05%	80.4%	52.85%
Selling, General & Admin	$1.820M	$1.880M	$3.980M
YoY Change	-54.27%	-61.87%	1.53%
% of Gross Profit	2065.06%	498.52%	2662.47%
Research & Development	$187.8K	$353.6K	$4.259M
YoY Change	-95.59%	-92.54%	0.67%
% of Gross Profit	213.04%	93.77%	2849.35%
Depreciation & Amortization	$50.00K	$60.00K	$70.00K
YoY Change	-28.57%	-25.0%	-36.36%
% of Gross Profit	56.73%	15.91%	46.83%
Operating Expenses	$2.184M	$782.6K	$8.376M
YoY Change	-73.92%	-92.03%	1.12%
Operating Profit	-$2.021M	-$313.5K	-$8.093M
YoY Change	-75.03%	-96.67%	1.36%
Interest Expense	$10.00K	$6.064K	$60.00K
YoY Change	-83.33%	-92.42%	-25.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.010M	-$2.640M	-$8.030M
YoY Change	-74.97%	-71.7%	0.57%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.009M	-$307.5K	-$8.029M
YoY Change	-74.98%	-96.71%	1.63%
Net Earnings / Revenue	-1231.85%	-65.55%	-2838.66%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.792M	-$3.667M	-$11.31M
COMMON SHARES
Basic Shares Outstanding	18.07M shares	18.07M shares	17.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.800M	$13.00M	$33.30M
YoY Change	-70.57%	-66.58%	-45.5%
Cash & Equivalents	$3.228M	$12.96M	$19.19M
Short-Term Investments	$0.00	$0.00	$14.10M
Other Short-Term Assets	$22.27K	$500.0K	$800.0K
YoY Change	-97.22%	-54.55%	-11.11%
Inventory	$186.9K	$223.5K	$431.9K
Prepaid Expenses
Receivables	$9.939K	$20.99K	$10.39K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.381M	$13.68M	$34.54M
YoY Change	-81.52%	-66.26%	-44.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$37.53K	$127.1K	$331.0K
YoY Change	-88.66%	-68.31%	-40.49%
Goodwill	$0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$195.4K	$100.0K	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$233.0K	$253.7K	$457.6K
YoY Change	-49.1%	-61.22%	-38.8%
TOTAL ASSETS
Total Short-Term Assets	$6.381M	$13.68M	$34.54M
Total Long-Term Assets	$233.0K	$253.7K	$457.6K
Total Assets	$6.614M	$13.94M	$34.99M
YoY Change	-81.1%	-66.18%	-44.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$379.8K	$1.279M	$2.004M
YoY Change	-81.05%	39.2%	68.13%
Accrued Expenses	$800.0K	$1.600M	$3.700M
YoY Change	-78.38%	-58.97%	42.31%
Deferred Revenue	$4.007M	$0.00	$72.19K
YoY Change	5450.44%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.107M	$2.888M	$5.848M
YoY Change	-81.07%	-41.92%	50.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.107M	$2.888M	$5.848M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$7.885M	$2.888M	$5.887M
YoY Change	33.94%	-42.55%	51.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.140M	-$131.0M	-$111.1M
YoY Change	-95.37%	27.08%	44.93%
Common Stock	$203.00	$1.807K	$1.780K
YoY Change	-88.6%	3.02%	6.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.271M	-$1.488M	-$2.900M
YoY Change
Total Liabilities & Shareholders Equity	$6.614M	$13.94M	$34.99M
YoY Change	-81.1%	-66.18%	-44.64%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	-$2.009M	-$307.5K	-$8.029M
YoY Change	-74.98%	-96.71%	1.63%
Depreciation, Depletion And Amortization	$50.00K	$60.00K	$70.00K
YoY Change	-28.57%	-25.0%	-36.36%
Cash From Operating Activities	-$3.140M	-$2.790M	-$5.750M
YoY Change	-45.39%	-65.34%	-8.73%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change	-100.0%	-100.0%	-80.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$4.670M
YoY Change	-100.0%	-100.0%	396.81%
Cash From Investing Activities	$0.00	$0.00	$4.660M
YoY Change	-100.0%	-100.0%	423.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-3.140M	-2.790M	-5.750M
Cash From Investing Activities	0.000	0.000	4.660M
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-3.140M	-2.790M	-1.090M
YoY Change	188.07%	-85.19%	-79.85%
FREE CASH FLOW
Cash From Operating Activities	-$3.140M	-$2.790M	-$5.750M
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$3.140M	-$2.790M	-$5.740M
YoY Change	-45.3%	-65.13%	-8.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	flks	Contractwith Customer Refund Period ContractwithCustomerRefundPeriod	P30D
	flks	Contractwith Customer Refund Period ContractwithCustomerRefundPeriod	P14D
	flks	Sales Discounts SalesDiscounts	202000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	83247	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-44116	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	79864	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-191380	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-64800	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	130196	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-283463	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	303	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001615219
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18069476	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Flex Pharma, Inc.
	dei	Entity Small Business EntitySmallBusiness	true
CY2017Q4	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3712221	USD
CY2018Q3	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	1554679	USD
CY2017Q4	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1850115	USD
CY2018Q3	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	610000	USD
CY2018Q3	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	609222	USD
CY2017Q4	flks	Accrued Research And Development Expense Other Current AccruedResearchAndDevelopmentExpenseOtherCurrent	652285	USD
CY2018Q3	flks	Accrued Research And Development Expense Other Current AccruedResearchAndDevelopmentExpenseOtherCurrent	23808	USD
CY2018Q2	flks	Cash Retention Bonuses Payable CashRetentionBonusesPayable	1210000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	675075	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3266879	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1698323	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	250991	USD
CY2018Q2	flks	Cash Retention Bonuses Payable Upon Changein Control CashRetentionBonusesPayableUponChangeinControl	500000	USD
CY2018Q2	flks	Cash Retention Bonuses Payable Upon Employeesin Good Standing CashRetentionBonusesPayableUponEmployeesinGoodStanding	710000	USD
CY2017Q4	flks	Debt Securities Availableforsale Significant Unrealized Loss Position Numberof Positions DebtSecuritiesAvailableforsaleSignificantUnrealizedLossPositionNumberofPositions	0	security
CY2018Q3	flks	Numberof Retained Employees NumberofRetainedEmployees	7	employee
	flks	Numberof Retained Employees NumberofRetainedEmployees	7	employee
	flks	Common Stock Numberof Votes CommonStockNumberofVotes	1	vote
	flks	Percentage Decreasein Company Workforce PercentageDecreaseinCompanyWorkforce	0.60
	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	7100	USD
	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	0	USD
CY2017Q3	flks	Sales Discounts SalesDiscounts	82000	USD
CY2018Q3	flks	Sales Discounts SalesDiscounts	2000	USD
	flks	Sales Discounts SalesDiscounts	19000	USD
CY2018Q2	flks	Severance Benefits Payable Upon Changein Controland Termination Without Cause SeveranceBenefitsPayableUponChangeinControlandTerminationWithoutCause	1125000	USD
CY2018Q2	flks	Sharebased Compensation Arrangementby Sharebased Payment Award Numberof Employees Granted Options SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofEmployeesGrantedOptions	7	employee
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2004440	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1279258	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10385	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20993	USD
CY2017Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	107595	USD
CY2018Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	16437	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	227980	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	284725	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1247	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140184630	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	142000936	USD
CY2017Q3	us-gaap	Advertising Expense AdvertisingExpense	1158000	USD
	us-gaap	Advertising Expense AdvertisingExpense	3073000	USD
CY2018Q3	us-gaap	Advertising Expense AdvertisingExpense	20000	USD
	us-gaap	Advertising Expense AdvertisingExpense	792000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1004781	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3266879	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	278390	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1698323	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3132361	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2583348	shares
CY2017Q4	us-gaap	Assets Assets	34992772	USD
CY2018Q3	us-gaap	Assets Assets	13938069	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	34535137	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	13684384	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	38	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1285	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	14130970	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	14129723	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8472	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2017Q4	us-gaap	Cash Cash	19186036	USD
CY2018Q3	us-gaap	Cash Cash	12961126	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12961126	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22542635	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20405319	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19312631	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13087721	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2137316	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6224910	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17972166	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18069476	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17797178	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18066767	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1780	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	1807	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9327808	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26404828	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2638373	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19912225	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	72188	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	148756	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	373187	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	91937	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	355816	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	8191315	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	6	security
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	58821	USD
CY2018Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	53919	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	39214	USD
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
	us-gaap	Depreciation Depreciation	250563	USD
	us-gaap	Depreciation Depreciation	176954	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.54
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	874246	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	430560	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2481000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4934937	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14520596	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1959872	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8651808	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-274525	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-725182	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22953	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3848	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1309611	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2161081	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9227	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2017Q3	us-gaap	Interest Income Operating InterestIncomeOperating	77339	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	227535	USD
CY2018Q3	us-gaap	Interest Income Operating InterestIncomeOperating	28210	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	139612	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	431891	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	223519	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17411	USD
CY2018Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7240	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	414480	USD
CY2018Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	216279	USD
CY2017Q3	us-gaap	Inventory Write Down InventoryWriteDown	15000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	34000	USD
CY2018Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	85000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	38551	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-11537	USD
CY2017Q4	us-gaap	Liabilities Liabilities	5886884	USD
CY2018Q3	us-gaap	Liabilities Liabilities	2887856	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34992772	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13938069	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5847670	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2887856	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	14129723	USD
CY2018Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2047	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118010	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19827530	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14120848	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21966893	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20463768	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-9332113	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26405131	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-2638373	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19913472	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9332113	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26405131	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2638373	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19913472	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	9823053	USD
	us-gaap	Operating Expenses OperatingExpenses	27624337	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	2917574	USD
	us-gaap	Operating Expenses OperatingExpenses	20728159	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9409452	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26632666	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2666583	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20053084	USD
CY2017Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	4305	USD
CY2018Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1247	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-22274	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	940518	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23364721	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1997751	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	98100	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	777102	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	478746	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	43286118	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	16117184	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4233	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1415	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2047	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	118010	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	331040	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127090	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4739360	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12730554	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	865765	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11720535	USD
CY2017Q4	us-gaap	Restricted Cash RestrictedCash	126595	USD
CY2018Q3	us-gaap	Restricted Cash RestrictedCash	126595	USD
	us-gaap	Restructuring Charges RestructuringCharges	1130000	USD
CY2018Q3	us-gaap	Restructuring Charges RestructuringCharges	212000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1130000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2018Q3	us-gaap	Restructuring Reserve RestructuringReserve	189927	USD
CY2017Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	USD
CY2018Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	189927	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111079275	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-130952530	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413601	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	991671	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P48M
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1126248	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	705387	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	714699	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	654544	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1517544	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	803600	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2580491	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2580639	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.65
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.28
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2580639	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.28
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.21
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.35
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.96
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.74
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M18D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y26D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y26D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	97310	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	29105888	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	11050213	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17386249	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17131887	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18066548	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17999877	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to clinical study accruals, estimates related to inventory realizability, stock-based compensation expense and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001615219-18-000061-index-headers.html	Edgar Link	pending
0001615219-18-000061-index.html	Edgar Link	pending
0001615219-18-000061.txt	Edgar Link	pending
0001615219-18-000061-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
flks-20180930.xml	Edgar Link	completed
flks-20180930.xsd	Edgar Link	pending
flks-20180930_cal.xml	Edgar Link	unprocessable
flks-20180930_def.xml	Edgar Link	unprocessable
flks-20180930_lab.xml	Edgar Link	unprocessable
flks-20180930_pre.xml	Edgar Link	unprocessable
flks2018093010-q.htm	Edgar Link	pending
flks20180930ex-311.htm	Edgar Link	pending
flks20180930ex-312.htm	Edgar Link	pending
flks20180930ex-321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

2018 Q4 Form 10-Q Financial Statement

#000161521918000061 Filed on November 05, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX Salarius Pharmaceuticals, Inc. Stock $slrx

2018 Q4 Form 10-Q Financial Statement

#000161521918000061 Filed on November 05, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx